C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis

Target: C1QA/C1QC Composite Score: 0.470 Price: $0.49▲3.4% Citation Quality: Pending neuroinflammation Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.470

Top 72% of 1875 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

D Mech. Plausibility 15% 0.38 Top 94%

C Evidence Strength 15% 0.40 Top 78%

B+ Novelty 12% 0.70 Top 43%

C Feasibility 12% 0.42 Top 82%

C+ Impact 12% 0.52 Top 82%

C Druggability 10% 0.40 Top 81%

C Safety Profile 8% 0.42 Top 81%

C Competition 6% 0.48 Top 87%

C Data Availability 5% 0.45 Top 84%

C Reproducibility 5% 0.40 Top 83%

Evidence

4 supporting | 5 opposing

Citation quality: 0%

Debates

1 session B+

Avg quality: 0.71

Convergence

0.00 F 5 related hypothesis share this target

From Analysis:

What are the specific molecular mechanisms by which C1Q components drive atherosclerotic plaque formation and progression?

While the study establishes C1QA and C1QC as diagnostic biomarkers and confirms their association with atherosclerosis risk, the mechanistic pathways linking complement activation to plaque pathogenesis remain unexplained. Understanding these mechanisms is critical since atherosclerosis is a major cause of vascular dementia and stroke-related neurodegeneration. Gap type: unexplained_observation Source paper: An integrative analysis of single-cell and bulk transcriptome and bidirectional mendelian randomization analysis identified C1Q as a novel stimulated risk gene for Atherosclerosis. (2023, Front Immunol, PMID:38179058)

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis starts from the claim that modulating C1QA/C1QC within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis starts from the claim that modulating C1QA/C1QC within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis starts from the claim that Atherosclerotic inflammation increases circulating IL-6 that crosses the compromised blood-brain barrier, priming cerebral endothelial cells to express C1Q. Brain microglia upregulate C1QC in response, driving complement-mediated synaptic pruning and cognitive decline. This mechanistic chain connects peripheral C1Q-driven atherosclerosis severity to neurodegeneration and vascular dementia. Framed more explicitly, the hypothesis centers C1QA/C1QC within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA/C1QC or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.40, novelty 0.70, feasibility 0.42, impact 0.52, mechanistic plausibility 0.38, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA/C1QC` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA/C1QC or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Systemic complement activation links to neuroinflammation. Identifier 24107782. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. C1Q mediates synapse loss in neurodegeneration models. Identifier 32393358. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Cardiovascular risk drives microglial activation. Identifier 36218221. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. C1Q involved in developmental synaptic pruning - disease relevance plausible. Identifier Multiple established. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Causal chain contains at least 4 unproven steps. Identifier NA - mechanistic critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. IL-6 crossing BBB is context-dependent; sufficiency unproven. Identifier NA - BBB assumption critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. CADASIL (NOTCH3mut) cross is mechanistically inappropriate for atherosclerosis. Identifier NA - model mismatch. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. C1Q expression patterns differ between mice and humans in CNS. Identifier Multiple species comparison studies. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Longest causal chain with weakest direct evidence for atherosclerosis. Identifier NA - synthesis critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.47`, debate count `1`, citations `0`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA/C1QC in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA/C1QC within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA/C1QC within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA/C1QC or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.40, novelty 0.70, feasibility 0.42, impact 0.52, mechanistic plausibility 0.38, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA/C1QC` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA/C1QC or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Systemic complement activation links to neuroinflammation. Identifier 24107782. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. C1Q mediates synapse loss in neurodegeneration models. Identifier 32393358. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Cardiovascular risk drives microglial activation. Identifier 36218221. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. C1Q involved in developmental synaptic pruning - disease relevance plausible. Identifier Multiple established. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Causal chain contains at least 4 unproven steps. Identifier NA - mechanistic critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. IL-6 crossing BBB is context-dependent; sufficiency unproven. Identifier NA - BBB assumption critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. CADASIL (NOTCH3mut) cross is mechanistically inappropriate for atherosclerosis. Identifier NA - model mismatch. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. C1Q expression patterns differ between mice and humans in CNS. Identifier Multiple species comparison studies. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Longest causal chain with weakest direct evidence for atherosclerosis. Identifier NA - synthesis critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.47`, debate count `1`, citations `0`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA/C1QC in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA/C1QC within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA/C1QC within the broader disease setting of neuroinflammation. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating C1QA/C1QC or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.40, novelty 0.70, feasibility 0.42, impact 0.52, mechanistic plausibility 0.38, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `C1QA/C1QC` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neuroinflammation, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA/C1QC or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Systemic complement activation links to neuroinflammation. Identifier 24107782. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

C1Q mediates synapse loss in neurodegeneration models. Identifier 32393358. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Cardiovascular risk drives microglial activation. Identifier 36218221. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

C1Q involved in developmental synaptic pruning - disease relevance plausible. Identifier Multiple established. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Causal chain contains at least 4 unproven steps. Identifier NA - mechanistic critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

IL-6 crossing BBB is context-dependent; sufficiency unproven. Identifier NA - BBB assumption critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

CADASIL (NOTCH3mut) cross is mechanistically inappropriate for atherosclerosis. Identifier NA - model mismatch. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

C1Q expression patterns differ between mice and humans in CNS. Identifier Multiple species comparison studies. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Longest causal chain with weakest direct evidence for atherosclerosis. Identifier NA - synthesis critique. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.47`, debate count `1`, citations `0`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA/C1QC in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting C1QA/C1QC within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Cardiovascular Risk Factors
Hypertension, hyperlipidemia"]
    B["Cerebrovascular Injury
White matter lesions"]
    C["C1QA and C1QC
Complement Protein Upregulation"]
    D["Classical Complement
Cascade Activation"]
    E["Glial Activation
Microglia and astrocyte"]
    F["Synaptic Complement
Tagging C3b opsonization"]
    G["Complement-Mediated
Synapse Elimination"]
    H["Vascular Dementia
Cognitive decline"]
    A --> B
    B --> C
    C --> D
    D --> E
    D --> F
    E --> G
    F --> G
    G --> H
    style C fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for C1QA/C1QC from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

9 citations 9 with PMID Validation: 0% 4 supporting / 5 opposing

✓ For (4)

No supporting evidence

No opposing evidence

(5) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 9CLIN 0GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Systemic complement activation links to neuroinfla…	Supporting	MECH	-	-	-	-	PMID:24107782	-
C1Q mediates synapse loss in neurodegeneration mod…	Supporting	MECH	-	-	-	-	PMID:32393358	-
Cardiovascular risk drives microglial activation	Supporting	MECH	-	-	-	-	PMID:36218221	-
C1Q involved in developmental synaptic pruning - d…	Supporting	MECH	-	-	-	-	PMID:Multiple established	-
Causal chain contains at least 4 unproven steps	Opposing	MECH	-	-	-	-	PMID:NA - mechanistic critique	-
IL-6 crossing BBB is context-dependent; sufficienc…	Opposing	MECH	-	-	-	-	PMID:NA - BBB assumption critique	-
CADASIL (NOTCH3mut) cross is mechanistically inapp…	Opposing	MECH	-	-	-	-	PMID:NA - model mismatch	-
C1Q expression patterns differ between mice and hu…	Opposing	MECH	-	-	-	-	PMID:Multiple species comparison studies	-
Longest causal chain with weakest direct evidence …	Opposing	MECH	-	-	-	-	PMID:NA - synthesis critique	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 4

Systemic complement activation links to neuroinflammation

PMID:24107782

C1Q mediates synapse loss in neurodegeneration models

PMID:32393358

Cardiovascular risk drives microglial activation

PMID:36218221

C1Q involved in developmental synaptic pruning - disease relevance plausible

PMID:Multiple established

✗ Opposing Evidence 5

Causal chain contains at least 4 unproven steps

PMID:NA - mechanistic critique

IL-6 crossing BBB is context-dependent; sufficiency unproven

PMID:NA - BBB assumption critique

CADASIL (NOTCH3mut) cross is mechanistically inappropriate for atherosclerosis

PMID:NA - model mismatch

C1Q expression patterns differ between mice and humans in CNS

PMID:Multiple species comparison studies

Longest causal chain with weakest direct evidence for atherosclerosis

PMID:NA - synthesis critique

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-21 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Therapeutic/Mechanistic Hypotheses: C1Q in Atherosclerosis

Hypothesis 1: C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion

Title: Classical complement activation blocks efficient clearance of apoptotic foam cells, accelerating necrotic core formation

Mechanism: C1Q binding to late apoptotic cells opsonizes them for phagocytic clearance, but chronic hyperactivation in the atherosclerotic intima leads to C5b-9 membrane attack complex deposition on surviving cells, causing secondary necrosis rather than homeostatic phagocytosis. This releases intracellular

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of C1Q-Atherosclerosis Mechanistic Hypotheses

Overview

These hypotheses form a coherent mechanistic framework linking the complement system to atherosclerosis pathogenesis. However, several suffer from a common limitation: they extrapolate from orthogonal disease contexts (autoimmunity, neurodegeneration) or in vitro systems to atherosclerosis without sufficient direct evidence. I evaluate each below, identifying weak links, counter-evidence, falsifying experiments, and revised confidence scores.

Hypothesis 1: C1Q-Mediated Defective Efferocytosis

Weak L

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Feasibility Assessment: C1Q-Atherosclerosis Mechanistic Hypotheses

Executive Summary

The SKEPTIC's critical evaluation substantially deflates confidence across all seven hypotheses. After removing inflated claims, two hypotheses warrant serious translational consideration (H1 and H2, both borderline ~0.52-0.58), while the remainder face significant druggability, model system, or causal chain validity challenges. The fundamental unresolved question—whether C1Q is a causal driver or a compensatory biomarker—must be answered before resource-intensive drug development.

Hypothes

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{"ranked_hypotheses":[{"title":"C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages","description":"C1Q binding to modified LDL particles triggers Syk kinase signaling and mitochondrial ROS production, providing a priming signal for NLRP3 inflammasome assembly in lesional macrophages. This mechanism creates a feed-forward inflammatory loop where C1Q-opsonized cholesterol crystals activate caspase-1, driving IL-1β/IL-18 secretion and perpetuating plaque inflammation. The hypothesis leverages the CANTOS trial precedent for IL-1β-targeted therapy in atherosclerosis, offering a clear t

Price History

7d Trend

↔

Stable

7d Momentum

▲ 3.5%

Volatility

Low

0.0119

Events (7d)

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (9)

Incidence of distress and associated factors in women undergoing breast diagnostic evaluation.

Western journal of nursing research (2014) · PMID:24107782

No extracted figures yet

The biological classification of mental disorders (BeCOME) study: a protocol for an observational deep-phenotyping study for the identification of biological subtypes.

BMC psychiatry (2020) · PMID:32393358

No extracted figures yet

Epigallocatechin-3-gallate alleviates galactose-induced aging impairment via gut-brain communication.

Food & function (2022) · PMID:36218221

No extracted figures yet

Paper:Multiple established

No extracted figures yet

Paper:Multiple species comparison studies

No extracted figures yet

Paper:NA - BBB assumption critique

No extracted figures yet

Paper:NA - mechanistic critique

No extracted figures yet

Paper:NA - model mismatch

No extracted figures yet

Paper:NA - synthesis critique

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.50

32.3th percentile (776 hypotheses)

Tokens Used

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

0.00 tokens

Lower is better (baseline: 2000)

Cost per Citation

0.00 tokens

Lower is better (baseline: 1000)

Cost per Score Point

0.00 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.050

10% weight of efficiency score

Adjusted Composite

0.520

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for C1QA/C1QC.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for C1QA/C1QC →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages

Score: 0.631 | neuroinflammation

C1Q-Induced Foam Cell Formation via Scavenger Receptor Upregulation

Score: 0.620 | neuroinflammation

C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion

Score: 0.600 | neuroinflammation

C1Q-Angiogenic Axis Promoting Plaque Neovascularization

Score: 0.530 | neuroinflammation

NETosis Amplification by C1Q in Plaque Neutrophils

Score: 0.500 | neuroinflammation

Estimated Development

Estimated Cost

Timeline

0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF plasma IL-6 levels (ELISA, pg/mL) are stratified into high (≥8 pg/mL) vs. low (<4 pg/mL) tertiles in a cohort of 200 patients with confirmed vascular dementia (NINDS-AIREN criteria, MoCA <20), THEN patients in the high IL-6 tertile will show ≥30% higher CSF C1Q concentrations (measured by Meso Scale Discovery assay) AND ≥25% lower CSF synaptic integrity markers (neurogranin, SNAP-25) compared to low IL-6 tertile at 12-month follow-up.

pending conf: 0.42

Expected outcome: Positive correlation between peripheral IL-6, brain C1Q expression, and synaptic loss

Falsified by: No significant difference in CSF C1Q (p > 0.05) OR no inverse correlation between CSF C1Q and synaptic markers between IL-6 tertiles, indicating the proposed peripheral-to-central C1Q axis does not exist

Method: Prospective cohort study: 200 vascular dementia patients (age 65-85) from ADNI-Vascular Cognitive Impairment cohort with annual plasma IL-6, CSF C1QA/C1QC (MSD multiplex), and CSF synaptic biomarkers (neurogranin, SNAP-25) measured over 24 months; multivariable regression controlling for age, sex, APOE4, baseline infarct volume

IF anti-C1QA/C1QC neutralizing antibody (intracerebroventricular infusion, 10 μg/day for 4 weeks) is administered to C57BL/6J mice subjected to bilateral carotid artery stenosis (VCID model), THEN microglial synaptic pruning will be reduced by ≥40% (measured by FlowJS analysis of CD68+ Iba1+ cells engulfing PSD95+ puncta) AND spatial memory performance will improve by ≥25% on Morris water maze (latency reduction) compared to vehicle-treated VCID mice within 6 weeks post-surgery.

pending conf: 0.38

Expected outcome: Significant reduction in complement-mediated synaptic pruning markers AND reversal of cognitive deficit

Falsified by: No statistically significant reduction in synaptic pruning (CD68/Iba1/PSD95 colocalization) AND no improvement in Morris water maze performance (p > 0.05) despite confirmed brain antibody penetration and C1Q target engagement (≥50% reduction in soluble C1Q in CSF)

Method: Bilateral carotid artery stenosis (BCAS) model in C57BL/6J mice (8-12 weeks old, n=20/group), randomized to anti-C1QA/C1QC antibody vs. vehicle, with behavioral testing and tissue collection at 6 weeks; complement inhibition confirmed by ELISA

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 C1QA — PDB 1PK6 Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What are the specific molecular mechanisms by which C1Q components drive atherosclerotic plaque formation and progression?

neuroinflammation | 2026-04-07 | archived

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages

Score: 0.63 · C1QA/C1QC

C1Q-Induced Foam Cell Formation via Scavenger Receptor Upregulation

Score: 0.62 · C1QA/C1QC

C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion

Score: 0.60 · C1QA/C1QC

Therapeutic Repurposing: C1-INH as Plaque-Stabilizing Agent

Score: 0.53 · C1R/C1S

C1Q-Angiogenic Axis Promoting Plaque Neovascularization

Score: 0.53 · C1QA/C1QC

→ View all analysis hypotheses

C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 4

✗ Opposing Evidence 5

Therapeutic/Mechanistic Hypotheses: C1Q in Atherosclerosis

Hypothesis 1: C1Q-Mediated Defective Efferocytosis Driving Necrotic Core Expansion

Critical Evaluation of C1Q-Atherosclerosis Mechanistic Hypotheses

Overview

Hypothesis 1: C1Q-Mediated Defective Efferocytosis

Weak L

Feasibility Assessment: C1Q-Atherosclerosis Mechanistic Hypotheses

Executive Summary

Hypothes

Price History

Clinical Trials (0)

📚 Cited Papers (9)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (0)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (5)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (0 edges)

3D Protein Structure

Source Analysis

What are the specific molecular mechanisms by which C1Q components drive atherosclerotic plaque formation and progression?

Community Feedback

Same Analysis (5)